Meftal%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520spas

# Meftal spas ## Overview Meftal spas is a combination product containing **Mefenamic Acid**, a nonsteroidal anti-inflammatory drug (NSAID), and **Dicyclomine Hydrochloride**, an anticholinergic antispasmodic. ## Primary Indications * Symptomatic relief of abdominal pain and cramps associated with gastrointestinal disorders, including irritable bowel syndrome and functional bowel disturbances. ## Adult Dosing * **Mefenamic Acid:** Typically 250 mg to 500 mg orally every 6 to 8 hours as needed, not to exceed 1500 mg per day. * **Dicyclomine Hydrochloride:** Typically 10 mg to 20 mg orally every 6 to 8 hours as needed. * **Meftal spas:** The dose of Meftal spas will depend on the specific formulation and concentration of each component. Consult product labeling for precise dosing. Generally, it is administered orally. ## Pediatric Dosing * Data regarding the use of Meftal spas in pediatric populations is limited. Mefenamic acid is sometimes used in children for fever or pain, typically dosed by weight (e.g., 5-10 mg/kg/dose every 6-8 hours). Dicyclomine is also used in pediatric populations for colic and spasms, with dosing highly dependent on age and weight. * **Due to the lack of established dosing for this specific combination product in children, use in pediatric patients is generally not recommended unless specifically directed by a healthcare provider and with careful monitoring.** ## Dose Adjustments * **Renal Impairment:** Mefenamic acid should be used with caution in patients with pre-existing renal disease. Dose reduction may be necessary, though specific guidelines for this combination are not well-established. * **Hepatic Impairment:** Mefenamic acid should be used with caution. * **Elderly:** Elderly patients may be at increased risk for adverse effects, particularly gastrointestinal bleeding and renal toxicity. Use with caution and consider the lowest effective dose. ## Contraindications * Hypersensitivity to mefenamic acid, dicyclomine, or any component of the formulation. * Active gastrointestinal bleeding or perforation. * History of NSAID-induced GI ulceration or bleeding. * Severe renal or hepatic impairment. * Myasthenia gravis. * Glaucoma (narrow-angle). * Obstructive uropathy. * Obstructive gastrointestinal disorders. * Severe ulcerative colitis. * Tachycardia. * Cystic fibrosis. * Infants less than 6 months of age (due to risk of respiratory depression with dicyclomine). ## Adverse Effects * **Common (Mefenamic Acid):** Diarrhea, nausea, vomiting, abdominal pain, dyspepsia, rash. * **Common (Dicyclomine):** Dry mouth, blurred vision, urinary retention, constipation, drowsiness, dizziness. * **Serious (Mefenamic Acid):** Gastrointestinal bleeding, ulceration, perforation, renal papillary necrosis, hepatic dysfunction, myocardial infarction, stroke, Stevens-Johnson syndrome, toxic epidermal necrolysis. * **Serious (Dicyclomine):** Confusion, hallucinations, severe constipation, paralytic ileus, tachycardia, exacerbation of glaucoma. ## Key Drug Interactions * **Anticoagulants (e.g., warfarin) and Antiplatelets (e.g., aspirin, clopidogrel):** Increased risk of bleeding when co-administered with mefenamic acid. * **Corticosteroids:** Increased risk of gastrointestinal ulceration and bleeding. * **Diuretics, ACE Inhibitors, Angiotensin II Receptor Blockers:** Reduced antihypertensive effect and increased risk of renal impairment with NSAIDs. * **Lithium:** NSAIDs can increase lithium levels. * **Methotrexate:** NSAIDs can increase methotrexate toxicity. * **Other NSAIDs and Salicylates:** Increased risk of adverse effects. * **Anticholinergic Agents:** Additive anticholinergic effects when combined with dicyclomine. * **Opioid Analgesics:** Dicyclomine may enhance the sedative effects. ## Monitoring * **Gastrointestinal:** Monitor for signs and symptoms of GI bleeding (e.g., melena, hematemesis, abdominal pain). * **Renal Function:** Monitor renal function, especially in patients with pre-existing renal disease or those at risk. * **Hepatic Function:** Monitor liver enzymes if long-term therapy is indicated. * **Hydration and Bowel Function:** Monitor for signs of dehydration and constipation, especially with dicyclomine. * **Ophthalmic:** Monitor for blurred vision and assess risk for angle-closure glaucoma. * **Urinary:** Monitor for urinary retention. ## Clinical Pearls * Meftal spas should be used at the lowest effective dose for the shortest duration necessary to minimize risks. * Administer with food or milk to reduce gastrointestinal upset. * Caution patients about operating machinery or driving until they know how this medication affects them, due to potential drowsiness and dizziness from dicyclomine. * Advise patients to avoid alcohol while taking this medication, as it can increase the risk of stomach bleeding. * Ensure patients are adequately hydrated to minimize risk of constipation from dicyclomine. *** **Disclaimer:** This information is for educational purposes only and does not constitute medical advice. It is essential for healthcare professionals to consult the most current prescribing information and relevant clinical guidelines for specific patient management.